Graph AI Raises $13.3M Series A to Scale the First AI-Native Operating System for Patient Safety

Led by Insight Partners with participation from Bessemer Venture Partners, the funding will accelerate Graph AI's expansion across the US and Europe.

PLEASANTON, Calif., Sept. 10, 2026 /PRNewswire/ -- Graph AI, developer of the Graph Safety AI-native patient safety platform, today announced a $13.3 million Series A financing led by Insight Partners, with participation from existing investor Bessemer Venture Partners.

Founded in 2024, Graph AI was created to address the operational inefficiencies and regulatory complexity facing modern pharmacovigilance and patient safety teams. Today, pharma teams devote much of their effort towards manual processing and operational workflows. Graph Safety enables intelligent software to take on that operational load, allowing safety experts to spend more time on analysis, decision-making, and areas where human judgement is essential.

Graph Safety combines AI with deterministic controls, validation layers, and end-to-end audit trails designed for regulated pharmacovigilance environments. Output and source data remain traceable, supporting customer validation, inspection readiness, and human oversight. The platform has been designed with reference to applicable regulatory requirements and evolving expectations for AI in medicines development and patient safety, including the FDA's risk-based credibility assessment framework for AI used to support regulatory decision-making, the EU Artificial Intelligence Act, and the CIOMS Working Group XIV report on Artificial Intelligence in Pharmacovigilance.

In live deployments, Graph Safety has reduced case processing turnaround time from more than three hours to under 10 minutes – a reduction of more than 90% and lowered operating costs by up to 66%.

"Pharma companies must strive to get patient safety exactly right, and almost none of them want to be in the business of integrating disparate tools to do it. Meanwhile the software and service providers they rely on haven't kept up with what AI can now do to drive accuracy and value for their pharma customers," said Richard Matus, Principal at Insight Partners. "We believe that's a perfect problem for an AI team that lives inside this industry with complete focus, and why we're proud to back Raghav and the Graph AI team as they scale."

"Since leading Graph AI's seed round, we've watched Raghav and the team turn a bold thesis into live enterprise deployments with measurable outcomes. Patient safety should run an intelligent, integrated platform - not fragmented tools and manual handoffs. We are thrilled to deepen our partnership alongside Insight Partners as Graph scales globally. This is what AI disrupting a services-heavy industry looks like." said Nithin Kaimal, Partner and India COO at Bessemer Venture Partners.

"Pharmacovigilance has traditionally scaled against rising case volumes by adding people and processes around legacy systems. We believe intelligence can change that. Graph Safety gives safety experts an intelligent system that takes on operational complexity, while keeping traceability, accountability, and human oversight at the center. We are not replacing human judgment—we are building technology that allows experts to apply it where it matters most," said Raghav Parvataraju, CEO, Graph AI.

Since raising its Seed round in October 2025, Graph AI has brought two modules to market: /intake, which captures and triages incoming adverse-event reports across every channel, and /nucleus, an intelligent safety database that automates case processing end to end. A third module, /report, for automated aggregate reporting, is also launching this September. The company has onboarded pharmaceutical and biotech customers across North America and other markets, and secured design partnerships for the modules ahead, including /signal, which surfaces emerging safety signals and patterns across cases.

About Graph AI

Graph AI develops Graph Safety, an AI-native pharmacovigilance platform designed to automate patient safety workflows while preserving traceability, accountability, and human oversight. Founded in 2024, the company serves pharmaceutical and biotechnology customers across global markets. For more information, visit graphsafety.ai.

About Insight Partners

Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of December 31, 2025, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 900 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has a global presence with leadership in London, Tel Aviv, and the Bay Area. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.

About Bessemer Venture Partners

Bessemer Venture Partners helps entrepreneurs lay strong foundations from inception to build long-standing companies. With more than 155 IPOs and 450-plus portfolio companies across industries, Bessemer supports founders and CEOs from seed through every stage of growth. Bessemer has backed industry defining companies including Anthropic, Abridge, Canva, LinkedIn, Perplexity, Pinterest, RocketLab, Shopify, ServiceTitan, Toast, and Twilio, and has $20 billion of assets under management. Bessemer invests globally, with investment teams located in San Francisco, Silicon Valley, New York, Boston, London, Bangalore, and Tel Aviv. www.bvp.com

SOURCE Graph AI